DWN12088 for Usual Interstitial Pneumonia

Phase-Based Progress Estimates
Daewoong Investigator site, Charleston, SC
Usual Interstitial Pneumonia+2 More
DWN12088 - Drug
All Sexes
What conditions do you have?

Study Summary

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Eligible Conditions

  • Usual Interstitial Pneumonia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: From Day 1 through Week 24

Week 24
Diffusing capacity of lung for carbon monoxide (DLCO) corrected for Hgb
Functional exercise capacity, assessed by the 6-minute walk test (6MWT) distance
Incidents of treatment-emergent adverse events
Quantitative high-resolution computed tomography
Rate of decline of FVC
Time to progression of IPF

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

DWN12088 Xmg Tablet (BID)
1 of 2
Placebo 0mg Tablet (BID)
1 of 2
Experimental Treatment
Non-Treatment Group

102 Total Participants · 2 Treatment Groups

Primary Treatment: DWN12088 · Has Placebo Group · Phase 2

DWN12088 Xmg Tablet (BID)
Experimental Group · 1 Intervention: DWN12088 · Intervention Types: Drug
Placebo 0mg Tablet (BID)
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from day 1 through week 24
Closest Location: Daewoong Investigator site · Charleston, SC
Photo of Charleston 1Photo of Charleston 2Photo of Charleston 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Usual Interstitial Pneumonia
0 CompletedClinical Trials

Who is running the clinical trial?

Daewoong Pharmaceutical Co. LTD.Lead Sponsor
149 Previous Clinical Trials
48,765 Total Patients Enrolled
JW SongPrincipal InvestigatorAsan Medical Center
SongPrincipal InvestigatorAIDS Malignancy Consortium

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.